# Cytovale

> Cytovale is a San Francisco-based medical diagnostics company that built IntelliSep, an FDA-cleared blood test that helps emergency departments identify patients at risk of sepsis in about eight minutes. Instead of hunting for a pathogen, the test reads the immune response by measuring the biomechanical properties of white blood cells using microfluidic deformability cytometry, high-speed imaging and machine learning. Founded on academic research that began in 2007 and incorporated in 2013, the company is applying its rapid host-response platform to one of medicine's most time-sensitive and deadly conditions.

- **Founded:** 2013
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Ajay Shah (Co-Founder & CEO), Henry Tse (Co-Founder & CTO), Dino Di Carlo (Co-Founder & Scientific Advisor)
- **Team size:** ~120
- **Products:** IntelliSep, IntelliSep Analyzer & Cartridge System
- **Notable:** First and only FDA-cleared cellular host-response sepsis test for emergency department use (cleared 2022)., Peer-reviewed study of 12,000+ patients showed a 39% reduction in sepsis mortality after IntelliSep adoption., Demonstrated a 0.76-1.28 day reduction in length of stay and 40% fewer blood cultures for low-risk patients.

## Products & services

- **IntelliSep** — FDA-cleared blood test that aids in the rapid identification of sepsis for adult patients presenting to emergency departments with signs and symptoms of infection. It analyzes the immune response by measuring the biomechanical properties of white blood cells and returns a risk band (probability of sepsis within 3 days) in approximately 8 minutes.
- **IntelliSep Analyzer & Cartridge System** — The benchtop instrument and single-use microfluidic cartridge that run the IntelliSep test using deformability cytometry, high-speed imaging and machine learning on a small blood sample.

## Achievements

- First and only FDA-cleared cellular host-response sepsis test for emergency department use (cleared 2022).
- Peer-reviewed study of 12,000+ patients showed a 39% reduction in sepsis mortality after IntelliSep adoption.
- Demonstrated a 0.76-1.28 day reduction in length of stay and 40% fewer blood cultures for low-risk patients.
- Average savings of ~$1,429 per patient tested reported at the flagship hospital site.
- Raised a $100M Series D in 2024, bringing total funding to roughly $224M.
- Brought advanced sepsis diagnostics to rural Louisiana hospitals, not just large academic centers.

## Latest updates

- **2025-06** — Peer-reviewed study confirmed IntelliSep was associated with a 39% reduction in sepsis mortality at a major hospital site.
- **2024-12** — A rural Louisiana hospital implemented IntelliSep, extending rapid sepsis detection beyond large trauma centers.
- **2024-10** — Cytovale completed a $100M Series D led by Sands Capital with CPP Investments joining, to expand commercialization.
- **2023-11** — Closed an $84M Series C to advance commercialization of IntelliSep.
- **2023-08** — Announced the commercial launch of the IntelliSep sepsis test for emergency departments.

## Links

- Website: https://cytovale.com
- LinkedIn: https://www.linkedin.com/company/cytovale
- Twitter/X: https://twitter.com/cytovale

---

Profile page: https://yespress.io/cytovale
Published by YesPress — https://yespress.io
Last updated: 2026-07-21